تأثير أدوية صرع غير محرضة لإنزيمات السيتوكروم الكبدية على الكثافة المعدنية للعظام

الملخص EN

Epilepsy is one of the most common chronic brain disorders that demands long term drug management.

A myriad of studies has linked hepatic enzyme inducing antiepileptic drugs (EIAEDs) to metabolic bone diseases.

Nevertheless, the studies that investigated the effect(s) of nonenzyme inducing antiepileptic drugs (NEI-AEDs) on bone health were controversial.

This study aimed at examining the postulated adverse effects of NEI-AEDs (valproate and lamotrigine) on bone and assessing their prevalence in Syrian epileptic patients.

We conducted a cross-sectional study in a cohort (n= 69) of young adult ambulatory epileptics on chronic (≥1 year) valproate or lamotrigine monotherapy, in comparison with 50 age- and sex-matched healthy subjects.

All participants underwent measurements of bone mineral density (BMD) and relevant biochemical indices.

Average age of patients was 26.37 ± 7.66 (±SD) years and females constituted 71%.

BMD values (g/cm2) at lumbar spine, femoral neck, and total hip as well as albumin-corrected calcium concentrations were lower in epileptics compared to healthy subjects, whereas the lower mean Z-scores in epileptics vs.

controls were not statistically significant.

Vitamin D deficiency was prevalent in up to 98.5% of epileptics and 92% of control subjects.

Our study provides evidence of adverse effects of epilepsy and/or NEI-AEDs on bone and proves epidemic prevalence of vitamin D deficiency in epileptics as well as healthy subjects.

These results call for implementation of preventive and therapeutic measures in epileptics on NEI-AEDs as a highrisk population and correcting vitamin D deficiency in the Syrian general population.